With marketing clearance from the US Food and Drug Administration that reduces the time to validate the use of its software with new hardware, digital pathology firm PathAI said that it plans to expand its reach by giving customers flexibility in the design of their lab systems and future-proofing its technology.

DM199 (rinvecalinase alfa; DiaMedica Therapeutics) has shown positive results for treating preeclampsia in part 1a of a phase 2 clinical trial, according to DiaMedica Therapeutics Inc.1

Similarly, PathAI is working on creating imaging biomarkers that can be used in clinical trials in cancer and liver diseases such as metabolic dysfunction-associated steatohepatitis (MASH).

Radiopharmaceuticals represent a rapidly advancing field in oncology, using radioactive compounds to both detect and treat cancer at the molecular level. This article explores how targeted radiation is improving patient outcomes while reducing systemic toxicity.

Radiopharmaceuticals

In this episode, Ayesha speaks with Ebrahim S. Delpassand, MD, Founder and CEO of RadioMedix, a company developing innovative radiopharmaceuticals for cancer diagnosis, monitoring and treatment.

He describes the science behind Cidara’s Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month’s readout, and how FDA discussions around this have been.

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of urea cycle disorders (UCDs) by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending dose study was initiated.

A key part of what makes Y-mAbs Therapeutics’ two-step bispecific fusion protein and radiotherapeutic effective comes down to concentration.